Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition
暂无分享,去创建一个
[1] C. Ustun,et al. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. , 2019, Blood advances.
[2] R. Larson,et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.
[3] R. Moriggl,et al. The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis , 2019, Haematologica.
[4] M. Carroll,et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. , 2019, Blood advances.
[5] H. Hayashi,et al. A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. , 2018, Blood advances.
[6] S. Constantinescu,et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer , 2018, Leukemia.
[7] Maria R. Baer,et al. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions , 2017, Molecular Cancer Therapeutics.
[8] K. Mori,et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia , 2017, Investigational New Drugs.
[9] I. Slukvin,et al. Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines , 2017, International Journal of Hematology.
[10] Brian E. McIntosh,et al. Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells , 2015, Stem cell research.
[11] Rui Huang,et al. Megakaryocytic Differentiation of K562 Cells Induced by PMA Reduced the Activity of Respiratory Chain Complex IV , 2014, PloS one.
[12] E. Forsberg,et al. Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells. , 2014, Experimental hematology.
[13] P. Carmeliet,et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. , 2013, Blood.
[14] M. Caligiuri,et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. , 2013, Blood.
[15] U. Zanger,et al. Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..
[16] Bengt Phung,et al. Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3* , 2012, The Journal of Biological Chemistry.
[17] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[18] K. Mrózek,et al. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. , 2011, Hematology/oncology clinics of North America.
[19] Frank J T Staal,et al. Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. , 2011, Cell stem cell.
[20] M. Ono,et al. GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro , 2011, Platelets.
[21] K. Döhner,et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.
[22] Yu-Jen Chen,et al. Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[23] T. Haferlach,et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.
[24] Daishu Han,et al. The role of Tyro 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. , 2007, Haematologica.
[25] S. Bohlander,et al. Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations , 2006, The Journal of experimental medicine.
[26] Lina A. Thoren,et al. Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.
[27] S. E. Jacobsen,et al. Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. , 2005, Blood.
[28] M. Levis,et al. FLT3: ITDoes matter in leukemia , 2003, Leukemia.
[29] W. Hiddemann,et al. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] W. Berdel,et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.
[31] C. Shelly,et al. K562 cells resistant to phorbol 12-myristate 13-acetate-induced growth arrest: dissociation of mitogen-activated protein kinase activation and Egr-1 expression from megakaryocyte differentiation. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[32] I. Weissman,et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.
[33] T. Naoe,et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.
[34] R. Herrera,et al. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. , 1998, Experimental cell research.
[35] S. Goueli,et al. Sustained Activation of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Is Required for Megakaryocytic Differentiation of K562 Cells* , 1997, The Journal of Biological Chemistry.
[36] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[37] T. Mcclanahan,et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs , 1994, Nature.
[38] G. Marcucci,et al. implications for Axl as a potential therapeutic target FLT3 internal tandem duplication in human acute myeloid leukemia: Inhibition of the receptor tyrosine kinase Axl impedes activation of the , 2013 .
[39] Stuart Moss,et al. Current Status and Future Directions , 2013 .
[40] D. Gilliland,et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.